### Contents

**EDITORIAL**

1544  Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAne phenotype  
Jeong KY, Lee H

**OPINION REVIEW**

1551  New drugs for the treatment of metastatic colorectal cancer  
Cherri S, Libertini M, Zaniboni A

**REVIEW**

1561  Extracellular vesicles: General features and usefulness in diagnosis and therapeutic management of colorectal cancer  
Mammes A, Pasquier J, Mammes O, Conti M, Douard R, Loric S

1599  Radiomics in hepatocellular carcinoma: A state-of-the-art review  
Yao S, Ye Z, Wei Y, Jiang HY, Song B

1616  Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment  
Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A

1632  Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer  

1648  Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers  
Lv X, Xu G

**MINIREVIEWS**

1668  Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway  

1680  Liver tumors in children with chronic liver diseases  
Sintusek P, Phewplung T, Sampavat A, Poovorawan Y

1696  Non-surgical treatment of hilar cholangiocarcinoma  
ORIGINAL ARTICLE

Basic Study

1709 Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis
Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ

1725 Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma

1741 Preventive and inhibitive effects of Yiwei Xiaoyu granules on the development and progression of spasmolytic polypeptide-expressing metaplasia lesions
Chen WQ, Tian FL, Zhang JW, Yang XJ, Li YP

1755 Effects of dietary zinc deficiency on esophageal squamous cell proliferation and the mechanisms involved
Chen Y, Liu FX, Liu H

Case Control Study

1766 Genetic variation of TGF-BR2 as a protective genotype for the development of colorectal cancer in men
Stanilov N, Grigorova A, Velikova T, Stanilova SA

Clinical Trials Study

1781 Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer
Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK

SYSTEMATIC REVIEWS

1791 Colorectal cancer in Arab world: A systematic review

1799 Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review
Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissant J

1813 Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review

META-ANALYSIS

1833 Anatomical vs nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review and meta-analysis
Liu H, Hu FJ, Li H, Lan T, Wu H
LETTER TO THE EDITOR

1847  Hepatocellular carcinoma biomarkers, an imminent need

Zamora-León SP
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Wen-Wei Sung, MD, PhD, Associate Professor, Doctor, Surgeon, Department of Urology, School of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Taichung 40201, Taiwan. flutewayne@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Rosa M Jimenez Rodriguez, Pashtoon M Kasi, Monjur Ahmed, FlorinBurada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
November 15, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer

Katharina Joechle, Jessica Guenzle, Claus Hellerbrand, Pavel Strnad, Thorsten Cramer, Ulf Peter Neumann, Sven Arke Lang

ORCID number: Katharina Joechle 0000-0001-9120-1526; Jessica Guenzle 0000-0001-6008-3731; Claus Hellerbrand 0000-0001-9472-4461; Pavel Strnad 0000-0002-7122-6379; Thorsten Cramer 0000-0002-6462-239X; Ulf Peter Neumann 0000-0002-3831-8917; Sven Arke Lang 0000-0003-4455-5676.

Author contributions: Joechle K and Lang SA contributed to conception and design the article; Joechle K, Hellerbrand C and Strnad P contributed to acquisition of data, drafting the article; All authors contributed to critical revision for important content and approved the final manuscript.

Conflict-of-interest statement: The authors declare that they have no conflicting interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Abstract

The mammalian target of rapamycin (mTOR) acts in two structurally and functionally distinct protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Upon deregulation, activated mTOR signaling is associated with multiple processes involved in tumor growth and metastasis. Compared with mTORC1, much less is known about mTORC2 in cancer, mainly because of the unavailability of a selective inhibitor. However, existing data suggest that mTORC2 with its two distinct subunits Rictor and mSin1 might play a more important role than assumed so far. It is one of the key effectors of the PI3K/AKT/mTOR pathway and stimulates cell growth, cell survival, metabolism, and cytoskeletal organization. It is not only implicated in tumor progression, metastasis, and the tumor microenvironment but also in resistance to therapy. Rictor, the central subunit of mTORC2, was found to be upregulated in different kinds of cancers and is associated with advanced tumor stages and a bad prognosis. Moreover, AKT, the main downstream regulator of mTORC2/Rictor, is one of the most highly activated proteins in cancer. Primary and secondary liver cancer are major problems for current cancer therapy due to the lack of specific medical treatment, emphasizing the need for further therapeutic options. This review, therefore, summarizes the role of mTORC2/Rictor in cancer, with special focus on liver cancer.
focus on primary liver cancer but also on liver metastases.

Key Words: Mammalian target of rapamycin; Mammalian target of rapamycin complex 2; Rictor; Liver cancer; Liver metastases; Hepatocellular carcinoma; Cholangiocellular carcinoma

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Mammalian target of rapamycin complex 2 (mTORC2) has recently gained importance in cancer research, as it is one of the key effectors of the PI3K/AKT/mTOR pathway and stimulates cell growth, cell survival, metabolism, and cytoskeletal organization. Rictor, the central subunit of mTORC2, was found to be upregulated in different kinds of cancers and is associated with a bad prognosis. We herein discuss the implications of mTORC2 in primary and secondary liver cancer.

INTRODUCTION

The mammalian target of rapamycin (mTOR) is an atypical serine/threonine kinase that controls cell survival, proliferation, and metabolism through phosphorylation of its downstream targets. It acts in two structurally and functionally distinct protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), and can be activated by several stimulating factors as hypoxia, insulin, growth factors, or dysregulation of PI3K/Akt signaling[1,2]. However, upon deregulation, activated mTOR signaling is implicated in the hallmarks of cancer and associated with increased cell survival, uncontrolled cell proliferation, metabolic reprogramming, and aberrant angiogenesis[3], which makes it a promising target in anticancer therapy.

The incidence of primary liver cancer, such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocellular carcinoma (iCCC), is increasing worldwide. Systemic therapy options are limited for both cancer entities. Surgery offers the only chance for cure, although only a minority of patients with HCC or iCCC are eligible for resection. Moreover, the liver is one of the most frequent sites of metastases development. Indeed, in most cancer entities liver metastasis is associated with a dramatic decline of patient’s prognosis, further emphasizing the fundamental impact of this site. A deeper understanding of processes involved in either primary or secondary liver cancer is therefore urgently needed[4-6].

Due to the availability of (more or less) selective mTORC1 targeting agents such as rapamycin, the role of mTORC1 in cancer has been extensively studied for decades. In contrast, mTORC2 was less intensively analyzed, mainly because of the lack of selective pharmacologic inhibitors. However, the last decade has brought up several studies suggesting a role for mTORC2 in cancer. For instance, Rictor (rapamycin insensitive companion of TOR), the central subunit of mTORC2, was found to be upregulated in different kinds of cancer and is associated with impaired prognosis[7-10]. Evidence from primary and secondary liver cancer is summarized in Table 1. In addition, involvement of mTORC2/Rictor in a plethora of processes implicated in tumor growth and also metastasis have been reported[11]. Therefore, the present review summarizes the current knowledge regarding the role of mTORC2 in cancer with focus on primary and secondary liver cancer.

MTOR COMPLEXES AND SIGNALING

Although mTOR acts through the different complexes mTORC1 and mTORC2, both have several subunits in common: the catalytic kinase mTOR, the scaffolding protein
Table 1 Overexpression of mammalian target of rapamycin complex 2 and its mediators determine clinical outcome

<table>
<thead>
<tr>
<th>mTORC2 mediator</th>
<th>Associated with</th>
<th>Measured by</th>
<th>Ref.</th>
</tr>
</thead>
</table>
| Primary liver cancer | HCC | p-AKT
Ser473 overexpression | poor outcome (P < 0.02) | IHC | Hu et al[59] |
| | | Rictor overexpression | Reduced OS (P = 0.0029) | mRNA expression | Xu et al[60] |
| | | Rictor overexpression | Reduced RFS (P = 0.016) | IHC, mRNA expression | Kaibori et al[61] |
| | iCCC | p-AKT1 overexpression | Improved OS (P = 0.0137) | IHC | Lee et al[76] |
| | CRLM | Rictor overexpression | Reduced OS (P = 0.0004) | IHC | Wang et al[10] |
| | Breast cancer liver metastases | Data only available for primary CRC | | |
| | | Rictor expression | Increasing tumor stage | mRNA expression | Gulhati et al[69] |
| | | Rictor expression | Increasing tumor stage | IHC, mRNA expression | Shuhua et al[81] |
| | Melanoma liver metastases | Rictor positivity (primary tumor) | Reduced OS (P = 0.018) | IHC | Liang et al[100] |
| | Renal cancer liver metastases | Data only available for invasive ductal breast carcinoma | | |
| | Gastric cancer liver metastases | Rictor expression | Lymph node metastasis | IHC | Zhang et al[90] |
| | Pancreatic cancer liver metastases | Data only available for pancreatic cancer | | |
| | | Rictor expression | Tumor stage/metastatic disease | mRNA expression | Schmidt et al[101] |
| | | Rictor expression | Tumor stage, reduced RFS and OS (P = 0.012, P = 0.014) | IHC | Bian et al[110] |
| | | Rictor expression | Tumor stage, reduced RFS and OS | IHC | Schmidt et al[9] |

CRC: Colorectal cancer; CRLM: Colorectal liver metastases; HCC: Hepatocellular carcinoma; iCCC: Intrahepatic cholangiocarcinoma; IHC: Immuno-histochemistry; mTORC2: Mammalian target of rapamycin complex 2; OS: Overall survival; RFS: Recurrence-free survival.

mLST8, the regulatory subunit DEPTOR, and the stabilizing complex Tti1/Tel2. The distinct subunits of mTORC1 are Raptor and PRAS40. While Raptor is important for mTORC1 substrate specificity, stability, and regulation, PRAS40 acts as negative regulator of mTORC1. Activation of mTORC1 depends on nutrient (e.g., amino acids) and growth factor (e.g., insulin) signaling through the PI3K/AKT and Ras-MAPK cascades. Phosphorylated AKT (via the PI3K/AKT pathway) or ERK and RSK (via the Ras-MAPK cascade) inhibit the TSC1/2 complex, which in turn triggers RHEB-mediated activation of mTORC1 leading to phosphorylation of its substrates 4EBP1 and S6K1. The downstream effectors act as key regulators of cap-dependent and cap-independent mTORC1 translation[3] and regulate translation and transcription of different target genes (e.g., HIF1α, etc.) thereby being implicated in cell growth, proliferation, and metabolism[12].

mTORC2 consists of its specific subunits Rictor and mSin1. Similar to Raptor, Rictor controls mTORC2 stability, subcellular localization, and substrate identification. It is essential for mTORC2 function, as silencing Rictor leads to significant inhibition of AKT, the key substrate of mTORC2. mSin1 negatively regulates mTORC2 until PI3K-mediated growth factor signaling locates mSin1/mTORC2 to the plasma membrane and relieves its inhibition. In turn, PI3K-generated PIP3 activates mTORC2. Activated mTORC2/Rictor leads to phosphorylation of AKT at the Ser473 residue. AKT can also be phosphorylated at the Thr308 residue by PDK1, which is in turn attracted by PIP3. Importantly, AKT is one of the most frequently activated proteins in cancer, and its full activity is only achieved if both sites are phosphorylated[13,14]. On a functional
level, AKT is involved in many processes. Association with cell migration, invasion, increased tumor growth, and cell survival while inhibiting apoptosis and promoting proliferative processes including glucose uptake and glycolysis have been described [15,16]. Additional substrates of mTORC2 are the AGC kinases like the PKC (e.g., PKCα, PKCβ, PKCε) family, which control tumorigenesis, cell migration, and cytoskeletal remodeling, and SGK isoforms that are implicated in cell survival and resistance to chemotherapy.

Along with the essential role of Rictor for mTORC2 functioning, it also acts independently of mTORC2. Thr1135, one of the 37 phosphorylation sites of Rictor, was shown to be stimulated directly by growth factor signaling and to be sensitive to rapamycin, as it is targeted by S6k1, one of the downstream effectors of mTORC1[17, 18]. This mechanism is assumed to represent a regulatory link between mTORC1 and mTORC2 signaling and to be part of a reciprocally influenced feedback loop mechanism[19,20]. Moreover, Rictor was also described to be associated with complexes exhibiting oncogenic and tumor suppressor properties. For example, Rictor forms a complex with ILK, which is crucial for TGFβ1 mediated epithelial-to-mesenchymal transition (EMT) and cancer cell survival[16,21]. In contrast, the combination of Rictor with PCD4 acts in an anti-oncogenic manner, as renal cancer cells showed reduced metastatic ability[22].

IMPLICATIONS OF MTORC1 IN CANCER

Besides being implicated in many physiological processes such as glucose and lipid homeostasis, adipogenesis, maintaining muscle mass and function, brain and immune function, deregulation of mTORC1 signaling is not only associated with diseases such as diabetes, neurodegeneration, and cancer. As described above, mTORC1 is activated by the oncogenic pathways PI3K/Akt and Ras-MAPK cascade. However, the oncogenic pathways are frequently mutated, resulting in hyperactivation of mTORC1, which is found in many human cancers[1]. Hyperactivated mTORC1 and its association with tumorigenesis are also seen in tuberous sclerosis, a familial cancer syndrome defined by the loss of the TSC1/2 complex, a negative regulator of mTORC1. Downstream of mTORC1, its role in carcinogenesis is linked to metabolic reprogramming in cancer cells. One example is the Warburg effect; aerobic glycolysis is controlled by mTORC1 via increased translation of HIF1α that in turn regulates the expression of glycolytic enzymes[23]. mTORC1 is also associated with upregulation of genes involved in lipogenesis by activation of the transcription factor SREBP1 through phosphorylation of Lipin1 and S6k1[24,25]. The latter was shown to be a major mechanism to promote growth and proliferation in breast cancer cells[26]. mTORC1-mediated phosphorylation of S6k1 is not only involved in lipogenesis but also in purine and pyrimidine synthesis leading to a rapid DNA duplication in cancer cells [27,28]. Aside from its control in cancer cell metabolism, mTORC1 is also involved in the regulation of autophagy and macropinocytosis.

The implications of mTORC1 in cancer are widely studied because of the availability of rapamycin as a selective mTORC1 inhibitor. However, rapamycin analogs (rapalogs) have only shown limited efficacy in cancer therapy. While inhibition of mTORC1 by rapamycin blocks phosphorylation of S6k1, phosphorylation of 4EBP1 is not fully blocked[29]. Therefore, 4EBP1-regulated translation of proteins involved in tumorigenesis is not inhibited. Another reason for the limited efficacy of rapamycin and rapalogs is explained by compensatory upregulation of AKT through phosphorylation of its Thr308 and Ser473 residue[30,31] as inactivated S6k1 no longer prevents suppression of insulin-PI3K signaling[32,33]. Moreover, treatment with rapalogs may increase micropinocytosis and autophagy leading to enhanced cell proliferation and survival[34,35].

IMPLICATIONS OF MTORC2 IN CANCER

Compared with mTORC1, much less is known about the role of mTORC2 in cancer, although existing data suggest mTORC2 to be of importance. Particularly, it is one of the key effectors of the PI3K/AKT/mTOR pathway and stimulates cell growth, cell survival, metabolism, and cytoskeletal organization.
**Tumorigenesis**

As described above, AKT is the key downstream target of mTORC2 signaling and one of the most commonly activated proteins in cancer[36,37] with its isoforms AKT1 and AKT2 being the main effectors in tumorigenesis[38]. With more than 200 AKT substrates, the different isoforms seem to have unique roles in tumorigenesis. While AKT1 increases tumor development and reduces tumor invasion, the expression of AKT2 has the opposite effect[39]. Frequently, hyperactivated AKT is found in different kinds of cancers. For example, hyperactivation of AKT caused by a somatic mutation was found to induce B-cell lymphoma, in contrast to wild-type AKT[40]. The somatic mutation was also found in breast, colorectal, and ovarian cancer. In addition to somatic mutations, hyperactivation of AKT may also occur because of activating upstream mutations in PI3K or deletions in PTEN, a tumor suppressor[41]. AKT has several substrates in common with SGK family members, another downstream target of mTORC2. Hence, SGK is similarly implicated in cell growth and proliferation[42]. Its isoform SGK3 is dependent on PDK1 signaling to induce tumor growth and adopted the role of AKT in tumorigenesis in PI3K mutated cancer cells[43]. AKT and SGK, which are different isoforms of PKC, are also involved in tumorigenesis. PKC-ε, PKC-α/ι, and PKC-β are known oncogenes with PKC-λ/ι and PKC-β for example being involved in colon carcinogenesis[44,45]. Mechanisms by which mTORC2 is involved in tumorigenesis are shown in Figure 1.

**Metastasis**

Cell migration and invasion are the two key components of metastasis that are affected by mTORC2 through different pathways. On the one hand, phosphorylation of AKT leads to activation of Rac1 through activation of Tiam1[46]. On the other hand, Rac1 is also upregulated by the suppression of its inhibitor RhoGD12, not only through AKT but also independent of AKT through PKCα activation[46,47] (Figure 2). Rac1 and RhoA are small GTPases known to have crucial roles in actin cytoskeletal rearrangement and cell migration, mainly by stimulating lamellipodia formation[48]. Upon mTORC2 knockdown, expression of Rac1 and RhoA is decreased, leading to a reduction of colorectal metastasis[49]. AKT1 is thus the AKT isoform implicated in metastasis. Silencing only AKT1 and not AKT2 reduces migration and invasion[50]. The gain of invasive behavior is explained by the EMT, and was reversible upon mTORC2 and mTORC1 inhibition, which was followed by an increase in cell-cell contacts and E-cadherin; vimentin, SMA, fibronectin, and MMP9 decreased[49].

**Metabolic reprogramming**

Metabolic reprogramming is a hallmark of cancer, and it allows tumor cells to receive and maintain their energy supply for rapid tumor growth[51]. mTORC2 was shown to control c-Myc, a regulator of the Warburg effect, by phosphorylation of class IIa HDAC and acetylation of FoxO in both an AKT dependent and independent manner, thereby increasing glycolysis[52]. Increases of glucose and acetate cause acetylation of Rictor, which in turn maintains mTORC2 signaling[53]. Besides glycolysis, mTORC2 also controls cystine uptake and glutathione metabolism. Phosphorylation of SLC7A11 thereby allows tumor cells to focus mainly on survival rather than proliferation if the extracellular environment changes[54]. In addition to energy supply, metabolic reprogramming can also be involved in drug resistance, as mTORC2 was shown to act as a central link between glucose metabolism and resistance to EGFR tyrosine kinase inhibitors[55].

**Drug resistance**

As mentioned above, metabolic reprogramming is one of the mechanisms of mTORC2-mediated drug resistance in cancer cells. Glucose metabolism has been linked not only to resistance to EGFR tyrosine kinase inhibitors[55] but also has caused Rictor acetylation that can be achieved by either glucose or acetate. Rictor acetylation induces auto-activation of mTORC2 signaling despite the absence of upstream growth factor signaling leading to resistance to EGFR-, PI3K- and AKT-targeted therapies[56]. Furthermore, Rictor utilizes inhibition of apoptosis by activation of NF-κB as another mechanism to develop resistance to chemotherapy[57]. Interestingly, the process could be overcome only by Rictor and not by AKT inhibition, suggesting that NF-κB is an AKT-independent mTORC2 downstream effector. In contrast, the positive feedback mechanism between amplified Rictor, known to occur in many cancers, and AKT leads to constant AKT activation, inducing not only tumor progression but also drug resistance[11].
Figure 1 Mechanism by which mammalian target of rapamycin complex 2 participates in tumorigenesis. mTOR: Mammalian target of rapamycin; mTORC2: mTOR complex 2.

Figure 2 Mechanism by which mammalian target of rapamycin complex 2 participates in metastasis. mTOR: Mammalian target of rapamycin; mTORC2: mTOR complex 2.

**MTORC2 IN PRIMARY LIVER CANCER**

**Hepatocellular carcinoma**

HCC is the most common primary liver cancer and one of the main cancer-related deaths worldwide, with increasing incidence in recent years. Systemic treatment options, with the multikinase inhibitors sorafenib and lenvatinib as the only approved drugs, are very limited in case of unresectability or unavailability to local treatment.
options. Activation of mTORC2 as determined by immunohistochemistry of phospho-AKT was detectable in 60% of HCCs[59]. Chromosomal gain of Rictor was described in 25% of HCCs, and its high expression was associated with a poor prognosis in HCC patients[60]. Similarly, Kaibori et al[61] found high expression of Rictor mRNA and protein and association with Rictor/Raptor ≥ 0.5 was a prognostic factor indicating poor recurrence-free survival. Rictor knockdown was shown to inhibit HCC cell growth in vitro[62], and AKT overexpression in vitro led to increased HCC development[63]. In the liver, there are two AKT isoforms, AKT1 and AKT2. Only AKT1 is phosphorylated and is thus activated by mTORC2 in c-Myc-induced HCC. AKT1 was the main driver of HCC formation, as AKT1 inhibition completely abolished c-Myc-induced tumor development[60]. Silencing of Rictor also led to inhibition of c-Myc-induced HCC formation[60]. In contrast, inhibition of AKT2 significantly reduced loss of PTEN-induced HCC formation[64]. Moreover, it was found that loss of Rictor completely inhibited sgrp/PTEN/c-Met HCC formation, leading to the assumption that mTORC2 regulates different AKT isoforms in HCC tumor development[65]. In contrast, the role of the other mTORC2 substrates, PKK and SGK in HCC, remains poorly characterized. However, mTORC2 also impacts HCC tumorigenesis through its role in metabolic reprogramming. Fatty acid and lipid synthesis are triggered by mTORC2 thereby leading to hepatic steatosis and tumor development[66]. The causal context was proven, as HCC development was completely abolished upon inhibition of fatty acid or sphingolipid synthesis[66]. Not only mTORC2-associated lipid synthesis but also gluconeogenesis impacts HCC cell survival. Khan et al[67] showed that blocking mTORC2 led to increased gluconeogenesis and decreased HCC cell proliferation and survival. In addition to the important role of mTORC2 in hepatocarcinogenesis, it also meteors to be involved in HCC metastasis and drug resistance: CHK1 is an enzyme known to be associated with HCC metastasis and EGFR-resistance. Inhibition of Rictor completely abolished CHK1-enhanced cell migration and invasion[8]. In line with that, pharmacologic mTORC1/mTORC2 inhibition reduced tumor cell metastasis, while there was no effect shown if the mTORC1 inhibitor rapamycin was used[8]. Moreover, following Rictor knockdown, CHK1-mediated resistance of HCC cells to EGFR-inhibitors decreased, and sensitivity to the drugs increased[8]. Similarly, the dual mTORC1/mTORC2 inhibitor OSI-027 reversed high MDR1 expression in HCC induced by doxorubicin and therefore increased chemosensitivity of doxorubicin. Combining both drugs led to inhibition of tumor growth in vitro and in vivo[68]. In that context, the investigators concluded that mTORC2 was the component responsible for the effect, as inhibition of mTORC1 alone resulted in a modest decrease of MDR1 expression.

While these data show an important role of mTORC2/Rictor in the tumorigenesis and tumor progression of HCC, it is also involved in pre-tumor conditions. For example, Reyes-Gordillo et al[69] showed that the AKT isoforms were activated in an in vivo two-hit model of alcoholic liver disease, leading to an increase of mTORC2 and inflammatory, proliferative, and fibrogenic genes. In line with the results, blocking of AKT1 and AKT2 led to a decrease in progression of liver fibrosis. In addition, mTORC2 was involved in the progression of nonalcoholic fatty liver disease (NAFLD) by dysregulation of white adipose tissue. Thereby, de novo lipogenesis, lipolysis, glycolysis, and increased glucose uptake by GLUT4 are the mechanisms by which mTORC2 regulates adiposity and NAFLD[70]. Besides alcoholic and nonalcoholic liver disease, viral hepatitis is one of the main risk factors for the development of HCC. In that context, increased AKT activity was demonstrated for hepatitis B and C. In hepatitis B, activation of AKT by the hepatitis B virus protein HBx leads to a persistent, noncytopathic virus replication[71]. In hepatitis C, its NS5A protease increases AKT activity by enhancing EGF-induced signal transduction[72].

**Intahepatic cholangiocarcinoma**

iCCC is a highly aggressive tumor entity with increasing incidence in recent years[73]. As systemic treatment only has partial benefits in advanced stages of iCCC[74], surgical resection remains the only curative option. Only a few studies examining the role of mTORC2 in iCCC exist. mTORC2 was found to be activated in almost 70% of iCCCs as determined by immunohistochemistry of phospho-AKT[75]. When examining the AKT isoforms, protein expression of phospho-AKT1 was shown in 34% of patients with iCCC and was associated with a favorable prognosis[76]. This unexpected result might be dependent on the mechanism of AKT activation triggering different downstream targets or a potential distinct role of AKT1 in iCCC. However, after Rictor knockdown, growth of iCCC cells in vitro was impaired and activated AKT was shown to cooperate with YAP to induce iCCC in mice[75]. Moreover, in liver-specific Rictor knockout mice, cholangiocarcinogenesis induced by AKT/Yap5127A
MTORC2 IN SECONDARY LIVER CANCER

Colorectal cancer liver metastasis

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths[80], with liver metastases being one of the most important predictors of poor long-term outcome. While it was shown that Rictor mRNA and protein are overexpressed in CRC[49] and expression is correlated with tumor progression, Dukes stage, lymph node metastasis, and impaired overall survival[10,81], there was no difference in Rictor expression between primary tumors and metastatic liver lesions[49]. However, Rictor expression in primary tumors with metastatic liver lesions was significantly higher than it was in primary tumors without metastatic disease[49]. Further, not only Rictor but also Raptor seems to be involved in colorectal liver metastases (CRLM), as knockdown of Rictor, as well as knockdown of Raptor, led to decreased migration and invasion of colorectal cancer cells in vitro[49]. In addition, in vivo knockdown of Raptor and Rictor in CRC cell lines impaired the formation of even micrometastases[49]. A study by Gulhati et al.[49] did not focus on the development of liver metastases, but they showed that mTORC2 via Rictor regulated actin cytoskeleton reorganization and cell migration through Rac1 and RhoA signaling. However, that is not the only mTORC2-associated mechanism involved in the formation of CRLM. TELO2, known to be essential for mTOR complex integrity, was found to be associated with colorectal tumorigenesis, migration, and invasion, as Rictor knockdown led to reduced TELO2-induced migratory and invasive behavior of colorectal cancer cells[82]. Moreover, colorectal metastasis is not controlled only via Rictor but also by mSin1. Wang et al.[83] showed that the tumor suppressor Pdc4 inhibited Sin1 translation leading to reduced mTORC2 activation and inhibited invasion of CRC cells. While the studies support the important oncogenic and metastatic potential of mTORC2 in CRC, it is also involved in resistance to systemic chemotherapeutic agents[81]. In particular, resistance of CRC cells to irinotecan, one of the three drugs of FOLFIRI, was resolved by treatment with mTORC1/2 inhibitors. Reiwa et al.[84] demonstrated that the combination of irinotecan and a mTORC1/2 blocker reduced migration and invasion in vitro as well as the development of liver metastases in vivo more effectively than irinotecan alone. Consistently, the knockdown of Rictor increased the sensitivity to irinotecan in SMAD4-negative colon cancer cells[85].

Breast cancer liver metastasis

Breast cancer accounts for almost one in four cancer cases among women, thereby representing the leading cause of cancer in over 100 countries worldwide[80]. Ma et al[86] recently reviewed the evidence that after the bony skeleton and the lung, breast cancer metastasizes most often to the liver, leading to very limited survival if untreated. Although many systemic therapies exist for metastatic breast cancer, overactive PI3K/AKT/mTOR signaling was shown to be associated with resistance to
therapy and with tumor progression[87-89]. The findings revealed 92% Rictor positivity in breast cancer lymph node metastases[90] as well as decreased tumor growth and migration but increased apoptosis upon Rictor knockdown[91]. Functionally, different pathways of mTORC2/Rictor involvement in breast cancer metastasis have been described. mTORC2 activates Rac1 through AKT phosphorylation and PKC-dependent downregulation of RhoGD12 leading to increased invasion and migration[46]. Rac1 is also activated by IBP, which was shown to regulate migration and invasion as well as actin cytoskeleton rearrangement and matrix metalloprotease production in breast cancer cells[92] by activation of the mTORC2/AKT/FoxO3a signaling pathway[93]. Moreover, interactions between mTORC2 and PRICKLE1 were shown to control cancer cell dissemination and motility[94]. Similarly, Rictor interacts with PKC-ζ to regulate breast cancer metastasis[90]. mTORC2 is further implicated in EMT in breast cancer by regulation of Snail and TGFß to control migration and invasion[21,95].

**Melanoma liver metastasis**
Melanoma liver metastasis occurs in up to 20% of patients with cutaneous melanoma and is one of the main prognostic factors of poor survival[96,97], mTORC2/Rictor is not only involved in PI3K dependent melanoma development[98] and metabolic reprogramming[99] but also in melanoma liver metastases. Rictor mRNA and protein were shown to be overexpressed in invasive melanoma[100] and to be significantly enhanced in metastatic compared with nonmetastatic melanoma[101]. Consistent with those findings, siRNA-mediated Rictor knockdown as well as pharmacological inhibition of mTORC2 not only led to reduced tumor cell motility, migration, and invasion in vitro[100,101] but also reduced melanoma liver metastasis in vivo[101,102]. Rictor depletion was shown to reduce AKT phosphorylation at the Ser473 and Thr308 residues and to inhibit the expression of MMP-2 and MMP-9[100,102]. Moreover, upon Rictor inhibition, interaction with stromal components such as hepatic stellate cells and HGF-induced melanoma cell activation/motility was impaired[101].

**Renal cancer liver metastasis**
Liver metastases occur in about one-fifth of patients with metastatic renal cancer[103], and surgical therapy remains the only strategy to improve survival (see Pinotti et al[104] for review). However, mTORC2 signaling might be a potential therapeutic target, as it is involved in the formation of renal cancer liver metastasis. Sun et al[105] showed that the proinflammatory cytokines TNFα and IL-6 increased upregulation of Rictor through the NF-κB pathway, thereby enhancing chemotaxis, invasion, and migration.
of renal cancer cells. Upon Rictor knockdown, the formation of renal cancer liver and lung metastases was significantly reduced[105]. Increased migration and invasion were also associated with activation of mTORC2/Akt/GSK3β/β-catenin signaling through TCTP overexpression[106]. Furthermore, pharmacological mTORC2 inhibition led to reduced migration by regulation of HIF2α and increase of cell-cell-junctions via E-cadherin[107].

Gastric and pancreatic cancer liver metastasis
Gastric cancer is the third leading cause of cancer-related deaths worldwide[80] with the liver being the most common side of gastric cancer metastasis[108]. Similarly, pancreatic cancer is one of the most fatal diseases with a 5-year survival rate of only 7%-109%. Rictor expression in gastric tumor samples was shown to correlate with TNM stage, lymph node metastasis, and poor long-term outcome. Positive staining of Akt at the Ser473 residue was associated with distant metastasis[7,110]. Also, Wang et al[111] reported the role of mTORC2 in gastric cancer metastasis, as DDR2 was found to enhance invasion and EMT through mTORC2 activation and AKT phosphorylation. Upon Rictor knockdown, proliferation, migration, and invasion of gastric cancer cells were significantly reduced while apoptosis was enhanced[110]. Regarding pancreatic cancer, Rictor protein expression was associated with overall survival after surgical resection. Patients with high or medium Rictor expression had significantly shorter survival compared with those with low expression[9]. Upon siRNA-mediated Rictor knockdown, pancreatic tumor cell proliferation and vascularization were significantly impaired and a trend toward fewer liver metastases was observed[9].

CONCLUSION
Compared with mTORC1, little is known about the role of mTORC2 and its distinct subunit Rictor, in cancer. However, the present review underlines the importance and high relevance of mTORC2 not only in tumorigenesis of primary liver cancer but also in the formation of metastatic liver lesions with different primaries. Thereby, mTORC2/Rictor and AKT, its main downstream effector, are associated with various steps of the metastatic cascade, including EMT, migration and invasion, and angiogenesis, and tumor cell proliferation through different signaling pathways. However, a more refined understanding of the implications of mTORC2 in primary and secondary liver cancer is essential to convert this knowledge into the development of specific mTORC2 targeting therapies.

REFERENCES
1 Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell 2017; 169: 361-371 [PMID: 28388417 DOI: 10.1016/j.cell.2017.03.035]
3 Kim LC, Cook RS, and Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene 2017; 36: 2191-2201 [PMID: 27748764 DOI: 10.1038/onc.2016.363]
9 Schmidt KM, Hellerbrand C, Rueemmele P, Michalski CW, Kong B, Kroemer A, Hackl C, Schlitt HJ, Geissler EK, Lang SA. Inhibition of mTORC2 component RICTOR impairs tumor growth in...
Joechle K et al. mTORC2 in liver cancer


21 Serrano I, McDonald PC, Lock FE, Dedhar S. Role of the integrin-linked kinase (ILK)/Rictor complex in TGF-β1-induced epithelial-mesenchymal transition (EMT). Oncogene 2013; 32: 50-60 [DOI: 10.1038/cand.2012.30]


26 Ricoult SJ, Yecies JL, Ben-Sahra I, Manning BD. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene 2016; 35: 1250-1260 [PMID: 26028026 DOI: 10.1038/onc.2015.179]


28 Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 2016; 351: 728-733 [PMID: 26912861 DOI: 10.1126/science.aad0489]


31 Lang SA, Moser C, Fichtner-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ,


39 Dillon RL, Marcorre T, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. *Cancer Res* 2009; 69: 5057-5064. [PMID: 19491266 DOI: 10.1158/0008-5472.CAN-08-4287]


41 Schmelzle T, Hall MN. TOR, a central controller of cell growth. *Cell* 2000; 103: 253-262. [PMID: 11057898 DOI: 10.1016/s0092-8674(00)0117-3]


Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.

L, Zhao B, Feng XH, Bai XL, Liang TB. Inhibition of mTORC2 Induces Cell-Cycle Arrest and
Chen BW

Riezman H, Hall MN. mTORC2 Promotes Tumorigenesis
via
Xu Z

Pten-null mice requires liver injury and is reversed by loss of AKT2.
KS, French S, Birnbaum MJ, Rountree CB, Stiles BL. Expansion of hepatic tumor progenitor cells in
carcinoma.
induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular
Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M. Increased lipogenesis,
carcinoma.
F, Zheng G, Chen X, Calvisi DF. Co-activation of AKT and c-Met triggers rapid hepatocellular
carcinoma development via the mTORC1/FASN pathway in mice. Sci Rep 2016; 6: 20484 [DOI:
26857837]: 10.1038/srep20484
RM, Dombrowski F, Evert M, Chen X, Calvisi DF, and Chen X. The mTORC2-Akt1 Cascade Is
Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatol Rev 2019; 70:
1600-1613 [PMID: 31062368]: 10.1002/hep.30967

Okumura T, Tokuhara K, Inoue K, Wada J, Oda M, Nishizawa M, Kon M. Influence of Rictor and
Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular

Villanueva A, Chiang DY, Newelll, Peix J, Thung S, Alsiet, C, Tovar V, Roayae S, Minguex B,
JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-
Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M. Increased lipogenesis,
induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular

KS, French S, Birnbaum MJ, Rountree CB, Stiles BL. Expansion of hepatic tumor progenitor cells in
Pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology 2010; 139:
Xu Z, Hu J, Cao H, Pilò MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF,
and Chen X. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via

Guri Y, Colombi M, Dazert E, Hinduskar SK, Roszik J, Moe S, Jenoe P, Heim MH, Riezman I,
Riezman H, Hall MN. mTORC2 Promotes Tumorogenesis via Lipid Synthesis. Cancer Cell 2017;

Khan MW, Biswas D, Ghosh M, Mandoli S, Chakrabarti S, Chakrabarti P. mTORC2 controls
cancer cell survival by modulating gluconeogenesis. Cell Death Discov 2015; 1: 1506 [PMID:
27551450]: 10.1038/cddiscovery.2015.16

L, Zhao B, Feng XH, Bai XL, Liang TB. Inhibition of mTORC2 Induces Cell-Cycle Arrest and
Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol

70 **Festuccia WT.** Regulation of Adipocyte and Macrophage Functions by mTORC1 and 2 in Metabolic Diseases. *Mol Nutr Food Res* 2021; 65: e1900768 [PMID: 32103588 DOI: 10.1002/mnr.201900768]


88 **Miller TW**, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in


